Overview
Diabetes Mellitus: Prevention strategies, predictors, treatment effects; kidney and other complications including cardiovascular outcomes. Utilization of EHR data to construct tools to improve the care of diabetes and comorbid conditions.
Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Endocrinology, Metabolism, and Nutrition,
Medicine
Member in the Duke Clinical Research Institute
·
2008 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Publications
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.
Journal Article Lancet Diabetes Endocrinol · December 2025 BACKGROUND: Uncertainty remains about effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on kidney outcomes in individuals with slowly progressive chronic kidney disease (eg, low albuminuria) and those at risk of large acute estimated glomerular ... Full text Link to item CiteBaseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
Journal Article J Am Soc Nephrol · November 6, 2025 Full text Link to item CiteInternational Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL.
Journal Article Diabetes Care · November 1, 2025 OBJECTIVE: To examine differences in case-fatality incidence among individuals with type 2 diabetes after major coronary or cerebrovascular events by geographic region and country income level. RESEARCH DESIGN AND METHODS: We studied ADVANCE, TECOS, and EX ... Full text Link to item CiteRecent Grants
GentiBio_GNTI-122-T1D-1001
Clinical TrialPrincipal Investigator · Awarded by GentiBio, Inc. · 2025 - 2035A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes
Clinical TrialPrincipal Investigator · Awarded by COUR Pharmaceuticals Development Co., Inc. · 2025 - 2034Endocrinology and Metabolism Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029View All Grants
Education, Training & Certifications
University of Virginia ·
1993
M.D.